You can buy or sell KALA and other stocks, options, ETFs, and crypto commission-free!
Kala Pharmaceuticals, Inc. Common Stock, also called Kala Pharmaceuticals, is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. Read More The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Simply Wall StMar 15
When Will Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Turn A Profit?
Kala Pharmaceuticals, Inc.’s (NASDAQ:KALA): Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. On 31 December 2018, the US$285m market-cap posted a loss of -US$66.7m for its most recent financial year. The most pressing concern for investors is KALA’s path to profitability – when will it breakeven? In this article, I will...
Seeking AlphaMar 11
Kala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q4 2018 Results - Earnings Call Transcript
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President, CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer Conference Call Participants David Maris - Wells Fargo Liana Moussatos - Wedbush Securities Yi Chen - H.C. Wainwright Operator Good day, and welcome to Kala Pharmaceuticals Fourth Quarter 2018 Earnings Conference Call. At t...
Yahoo FinanceMar 11
Kala Pharma: 4Q Earnings Snapshot
WALTHAM, Mass. (AP) _ Kala Pharmaceuticals Inc. (KALA) on Monday reported a loss of $25.2 million in its fourth quarter. On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 76 cents. Losses, adjusted to extinguish debt, were 75 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 52 cents per share. Kala Pharma shares have climbed 77 percent since the beginning of ...
-$0.76 per share